Quoin Pharmaceuticals Ltd DRC (QNRX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Quoin Pharmaceuticals Ltd DRC (QNRX) has a cash flow conversion efficiency ratio of -0.555x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.87 Million) by net assets ($8.77 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Quoin Pharmaceuticals Ltd DRC balance sheet quality to measure how much of total assets are equity-financed.
Quoin Pharmaceuticals Ltd DRC - Cash Flow Conversion Efficiency Trend (2015–2025)
This chart illustrates how Quoin Pharmaceuticals Ltd DRC's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore QNRX operating cash to total liabilities to assess how comfortably operating cash covers total debt obligations.
Quoin Pharmaceuticals Ltd DRC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Quoin Pharmaceuticals Ltd DRC ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
BAIYU Holdings Inc.
NASDAQ:BYU
|
-0.009x |
|
Digitree Group S.A
WAR:DTR
|
0.140x |
|
Kamdar Group (Malaysia) Bhd
KLSE:8672
|
0.002x |
|
Celyad SA
BR:CYAD
|
0.919x |
|
Jaya Trishindo Tbk PT
JK:HELI
|
0.022x |
|
Yoshitsu Co Ltd ADR
NASDAQ:TKLF
|
-0.191x |
|
Paras Petrofils Limited
NSE:PARASPETRO
|
N/A |
|
WAG Payment Solutions PLC
LSE:WPS
|
0.305x |
Annual Cash Flow Conversion Efficiency for Quoin Pharmaceuticals Ltd DRC (2015–2025)
The table below shows the annual cash flow conversion efficiency of Quoin Pharmaceuticals Ltd DRC from 2015 to 2025. For the full company profile with market capitalisation and key ratios, see how much is Quoin Pharmaceuticals Ltd DRC worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $13.12 Million | $-13.54 Million | -1.032x | -20.91% |
| 2024-12-31 | $9.20 Million | $-7.86 Million | -0.854x | +38.52% |
| 2023-12-31 | $5.66 Million | $-7.86 Million | -1.388x | -21.27% |
| 2022-12-31 | $7.41 Million | $-8.48 Million | -1.145x | +86.85% |
| 2021-12-31 | $657.03K | $-5.72 Million | -8.706x | -4397.13% |
| 2020-12-31 | $-6.61 Million | $-1.34 Million | 0.203x | +115.25% |
| 2019-12-31 | $4.30 Million | $-5.71 Million | -1.329x | +24.69% |
| 2018-12-31 | $3.73 Million | $-6.57 Million | -1.764x | -92.44% |
| 2017-12-31 | $5.43 Million | $-4.98 Million | -0.917x | -80.15% |
| 2016-12-31 | $7.40 Million | $-3.77 Million | -0.509x | +30.78% |
| 2015-12-31 | $2.70 Million | $-1.98 Million | -0.735x | -- |
About Quoin Pharmaceuticals Ltd DRC
Quoin Pharmaceuticals, Ltd., a late-stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases in the United States. The company's lead product is QRX003, a topical lotion, which is in phase 2 to treat netherton syndrome (NS); phase 1 in to treat peeling skin syndrome; and in pre-clinical stage to treat SAM syndrom… Read more